STOX1 and central nervous system cancer: However, this possibility could probably be ruled out because genetic alteration analysis demonstrated a <0.5% deletion of STOX1 gene in 1,122 glioma patients (LGG, n = 516 and GBM n = 606) patients (cBioPortal, https://www.cbioportal.org) (data not shown), suggesting that loss of STOX1 in glioma may be due to some upstream regulations instead.